Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties

European Journal of Pharmacology

Volumn 535, Issue 1-3, 2006, Pages 301-309

  Fantin, Marianna ^a,b   Quintieri, Luigi ^b   Kúsz, Erzsébet ^a   Kis, Emese ^a   Glavinas, Hristos ^c   Floreani, Maura ^b   Padrini, Roberto ^b   Duda, Erno ^a   Vizler, Csaba ^a  

^a INSTITUTE OF BIOCHEMISTRY   (Hungary)

^b UNIVERSITY OF PADOVA   (Italy)

^c SOLVO BIOTECHNOLOGY   (Hungary)

Author keywords

ABC transporter; Carboxylated metabolite; Endothelium; Macrophage; Pentoxifylline; TNF

Indexed keywords

1 (3 CARBOXYPROPYL)THEOBROMINE; 1 (4 CARBOXYBUTYL)THEOBROMINE; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; DRUG METABOLITE; LIPOPOLYSACCHARIDE; LISOFYLLINE; MULTIDRUG RESISTANCE PROTEIN 1; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME RELEASE; ENZYME SYNTHESIS; FIBROSARCOMA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPLASMIC VESICLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSARCOMA; HEMANGIOENDOTHELIOMA; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; P-GLYCOPROTEIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; SPODOPTERA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 33645389262     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.017     Document Type: Article

References (43)

1. J.L. Ambrus, S. Stadler, and M. Kulaylat Hemorheologic effects of metabolites of pentoxifylline (Trental) J. Med. 26 1995 65 75
2. E. Bakos, R. Evers, E. Sinko, A. Varadi, P. Borst, and B. Sarkadi Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions Mol. Pharmacol. 57 2000 760 768
3. B. Beerman, R. Ings, J. Mansby, J. Chamberlain, and A. McDonald Kinetics of intravenous and oral pentoxifylline in healthy subjects Clin. Pharmacol. Ther. 37 1985 25 28
4. D.R. Collingridge, and S. Rockwell Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rabdomyosarcomas and EMT6 mouse mammary carcinomas Int. J. Cancer 90 2000 256 264
5. S.P. Crouch, and J. Fletcher Effect of ingested pentoxifylline on neutrophil superoxide anion production Infect. Immun. 60 1992 4504 4509
6. M.S. Currie, K.M. Rao, J. Padmanabhan, A. Jones, J. Crawford, and H.J. Cohen Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production J. Leukoc. Biol. 47 1990 244 250
7. C.L. D'Hellencourt, L. Diaw, P. Cornillet, and M. Guenounou Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline Int. J. Immunopharmacol. 18 1996 739 748
8. C. Dominguez-Jimenez, D. Sancho, M. Nieto, M.C. Montova, O. Barreiro, F. Sanchez-Madrid, and R. Gonzales-Amaro Effect of pentoxifylline on polarization and migration of human leukocytes J. Leukoc. Biol. 71 2002 588 596
9. Z. Drobná, U. Stein, W. Walther, M. Barancik, and A. Breier Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdrl gene expression in multidrug resistant mouse leukemic L1210/VCR cells Gen. Physiol. Biophys. 21 2002 103 109
10. J. Fang, T. Akaike, and H. Maeda Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment Apoptosis 9 2004 27 35
11. J.C. Fantone, and P.A. Ward Polymorphonuclear leukocyte-mediated cell and tissue injury: oxygen metabolites and their relations to human disease Human Pathol. 16 1985 973 978
12. J.E. Frampton, and R.N. Brodgen Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders Drugs Aging 7 1995 480 503
13. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev., Cancer 2 2002 48 58
14. R.P. Gude, M.M. Binda, A.L. Boquete, and R.D. Bonfil Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline J. Cancer Res. Clin. Oncol. 127 2001 625 630
15. Z. Gyorfy, S. Benko, E. Kusz, B. Maresca, L. Vigh, and E. Duda Highly increased TNF sensitivity of tumor cells expressing the yeast delta 9-desaturase gene Biochem. Biophys. Res. Commun. 18 1997 465 470
16. J. Han, G. Huez, and B. Beutler Interactive effects of the tumor necrosis factor promoter and 3′-untranslated regions J. Immunol. 146 1991 1843 1848
17. H.J. Hinze, G. Bedessem, and A. Soder Structure of excretion products of 3,7-dimethyl-1-(5-oxo-hemyl)-xanthine (BL 191) in man Arzneim.-Forsch. 22 1972 1144 1151
18. H. Holtmann, T. Hahn, and D. Wallach Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability Immunobiology 177 1988 7 22
19. T. Janvilisri, H. Venter, S. Shahi, G. Reuter, L. Balakrishnan, and H.W. van Veen Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis J. Biol. Chem. 278 2003 20645 20651
20. A. Jull, J. Waters, and B. Arroll Pentoxifylline for treatment of venous leg ulcers: a systematic review Lancet 359 2002 1550 1554
21. M. Katori, D.M. Anselmo, R.W. Busuttil, and J.W. Kupiec-Weglinski A novel strategy against ischemia and reperfusion injury: cytoprotection with heme oxygenase system Transpl. Immunol. 9 2002 227 233
22. T.Y. Kim, W.I. Kim, R.E. Smith, and E.D. Kay Role of p27(Kip1) in cAMP- and TGF-beta2-mediated antiproliferation in rabbit corneal endothelial cells Invest. Ophthalmol. Visual Sci. 42 2001 3142 3149
23. Y.X. Li, K. Weber-Johnson, L.Q. Sun, N. Paschoud, R.O. Mirimanoff, and P.A. Coucke Effect of pentoxifylline on radiation-induced G2-phase delay and radiosensitivity of human colon and cervical cancer cells Radiat. Res. 149 1998 338 342
24. H.I. Lin, S.J. Chu, D. Wang, and N.H. Feng Pharmacological modulation of TNF production in macrophages J. Microbiol. Immunol. Infect. 37 2004 8 15
25. D. Moher, B. Pham, M. Ausejo, A. Saez, S. Hood, and G. Barber Pharmacological management of intermittent claudication Drugs 59 2000 1057 1070
26. S. Nataf, J.P. Louboutin, D. Chabannes, J.R. Feye, and J.Y. Muller Pentoxifylline inhibits experimental allergic encephalomyelitis Acta Neurol. Scand. 88 1993 97 99
27. M. Nicklasson, S. Bjorkman, B. Roth, M. Jonsson, and P. Hoglund Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans Chirality 14 2002 643 652
28. G.S. Oh, H.O. Pae, M.K. Moon, B.M. Choi, Y.G. Yun, J.S. Rim, and H.T. Chung Pentoxifylline protects L929 fibroblasts from TNF-alpha toxicity via the induction of heme oxygenase-1 Biochem. Biophys. Res. Commun. 302 2003 109 113
29. M. Otsuki, H. Saito, X. Xu, S. Sumitani, H. Kouhara, M. Kurabayashi, and S. Kasayama Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence Atherosclerosis 158 2001 121 128
30. L.E. Otterbein, J.K. Kolls, L.L. Mantell, J.L. Cook, J. Alam, and A.M. Choi Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury J. Clin. Invest. 103 1999 1047 1054
31. J.S. Pober, M.R. Slowik, L.G. De Luca, and A.J. Ritchie Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1 J. Immunol. 150 1993 5114 5123
32. G.C. Rice, P.A. Brown, R.J. Nelson, J.A. Bianco, J.W. Singer, and S. Bursten Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid Proc. Natl. Acad. Sci. U. S. A. 91 1994 3857 3861
33. B. Sarkadi, E.M. Price, R.C. Boucher, U.A. Germann, and G.A. Scarborough Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase J. Biol. Chem. 267 1992 4854 4858
34. A. Schwarz, C. Krone, F. Trautinger, Y. Aragane, P. Neuner, T.A. Luger, and T. Schwarz Pentoxifylline suppresses irritant and contact hypersensitivity reactions J. Invest. Dermatol. 101 1993 549 552
35. J. Semmler, U. Gebert, T. Eisenhut, J. Moeller, M.M. Schonharting, A. Allera, and S. Endres Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity Immunology 78 1993 520 525
36. C.W. Song, T. Hasegawa, H.C. Kwon, J.C. Lyons, and S.H. Levitt Increase in tumor oxygenation and radiosensitivity caused by pentoxifylline Radiat. Res. 130 1992 205 210
37. J. Turner, A.A. Frank, J.V. Brooks, P.M. Marietta, and I.M. Orme Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology Immunology 102 2001 248 253
38. A.M. van Furth, E.M. Verhard-Seijmonsbergen, R. van Furth, and J.A. Langermans Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes Immunology 91 1997 193 196
39. A. Viladkar, and M. Chitnis In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells Cancer Biother. 9 1994 143 151
40. C. Vizler, A. Rosato, F. Calderazzo, L. Quintieri, P. Fruscella, R. Wainstok de Calmanovici, A. Mantovani, A. Vecchi, P. Zanovello, and D. Collavo Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity Br. J. Cancer 77 1998 656 662
41. J.B. Weinberg, S.N. Mason, and T.S. Wortham Inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) messenger RNA (mRNA) expression in HL-60 leukemia cells bypentoxifylline and dexamethasone: dissociation of acivicin-induced TNF-alpha andIL-1 beta mRNA expression from acivicin-induced monocytoid differentiation Blood 179 1992 3337 3343
42. Z. Yang, M. Chen, and J.L. Nadler Lisofylline: a potential lead for the treatment of diabetes Biochem. Pharmacol. 69 2005 1 5
43. P. Zabel, F.U. Schade, and M. Schlaak Inhibition of endogenous TNF formation by pentoxifylline Immunobiology 187 1993 447 463